# Eduard van Gelderen > Eduard van Gelderen is a Series A investor at PSP Investments backing Medical and Health Care. See 4 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [PSP Investments](https://shizune.co/investors/profile/pspinvestments) - Location: Montréal, Canada - Total investments: 4 - Last investment: Jan 2021 - Lead investor: 50% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/eduard-van-gelderen-68b15111/ Eduard van Gelderen is a Series A investor at PSP Investments in Montréal focused on Medical and Health Care. Eduard van Gelderen - SVP and Chief Investment Officer @ Public Sector Pension Investment Board ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Medical | 1 | 25% | | Health Care | 1 | 25% | | Biotechnology | 1 | 25% | ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series A | 1 | 25% | | Series B | 1 | 25% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Valo Health | Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning-anchored computation to transform the drug discovery and development process. By integrating data across the drug development lifecycle, the discovery and development of life-changing treatments can be accelerated, with the potential to reducecost, time, and failure rate. The company's Opal Computational Platform™, a fully integrated, componentized, end-to-end drug development platform, offers a unique approach to therapeutic development, that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration. | $190M | Series B | Jan 11, 2021 | | | Valo Health | Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning-anchored computation to transform the drug discovery and development process. By integrating data across the drug development lifecycle, the discovery and development of life-changing treatments can be accelerated, with the potential to reducecost, time, and failure rate. The company's Opal Computational Platform™, a fully integrated, componentized, end-to-end drug development platform, offers a unique approach to therapeutic development, that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration. | $190M | Series B | Jan 11, 2021 | | | Valo Health | Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning-anchored computation to transform the drug discovery and development process. By integrating data across the drug development lifecycle, the discovery and development of life-changing treatments can be accelerated, with the potential to reducecost, time, and failure rate. The company's Opal Computational Platform™, a fully integrated, componentized, end-to-end drug development platform, offers a unique approach to therapeutic development, that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration. | $100M | Series A | Jul 01, 2019 | | | Valo Health | Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning-anchored computation to transform the drug discovery and development process. By integrating data across the drug development lifecycle, the discovery and development of life-changing treatments can be accelerated, with the potential to reducecost, time, and failure rate. The company's Opal Computational Platform™, a fully integrated, componentized, end-to-end drug development platform, offers a unique approach to therapeutic development, that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration. | $100M | Series A | Jul 01, 2019 | | 4 of 4 investments shown. ## Co-investors - [Global Founders Capital](https://shizune.co/investors/profile/global-founders-capital) — VC Fund, 4 deals together - [Longevity Vision Fund](https://shizune.co/investors/profile/longevity-vision-fund) — VC Fund, 4 deals together - [Atinum Partners](https://shizune.co/investors/profile/atinum-investment) — VC Fund, 2 deals together - [Atinum Partners](https://shizune.co/investors/profile/atinum-partners) — VC Fund, 2 deals together - [E Squared Capital Management](https://shizune.co/investors/profile/e-squared-capital-management-2) — VC Fund, 2 deals together - [Flagship Pioneering](https://shizune.co/investors/profile/flagship-ventures) — VC Fund, 2 deals together ## About PSP Investments VC Fund · Ottawa, Canada PSP Investments is one of Canada’s largest pension investment managers, with $116.8 billion of assets under management as at March 31, 2016. We invest funds for the pension plans of the Public Service, the Canadian Armed Forces, the Royal Canadian Mounted Police and the Reserve Force.Our skilled and dedicated team of more than 600 professionalsmanages a diversified global portfolio including stocks, bonds and other fixed-income securities, and investments in Private Equity, Real Estate, Infrastructure, Natural Resources and Private Debt.Our business offices are in Montreal, New York, London and Luxembourg. Our head office is in Ottawa. 5 contacts available at PSP Investments. | Name | Title | Profile | | --- | --- | --- | | Annie Sorich | TitleSenior Director, Strategy and Business Planning | https://shizune.co/investors/profile/annie-sorich | | David Court | Director | https://shizune.co/investors/profile/david-court | | Eduard van Gelderen | SVP and Chief Investment Officer | https://shizune.co/investors/profile/eduard-van-gelderen | | Loic Jule | Managing Director - Global Investment Partnerships Portfolio | https://shizune.co/investors/profile/loic-jule | | Nicholas Lenicheck | Senior Director, Capital Markets Alternatives | https://shizune.co/investors/profile/nicholas-lenicheck | ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund ## FAQ ### What does Eduard van Gelderen invest in? Eduard van Gelderen invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Eduard van Gelderen last invest? The most recent investment recorded for Eduard van Gelderen closed in Jan 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co